Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Tabelecleucel

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Rejects Atara’s blood Cancer Treatment
    FDA Rejects Atara’s blood Cancer Treatment

    13 Jan 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-ataras-therapy-rare-blood-cancer-2026-01-12/#:~:text=Jan%2012%20(Reuters)%20%2D%20The,down%2056%25%20in%20early%20trading.

    REUTERS
    13 Jan 2026
    Share Share
    Pierre Fabre Pharma Responds to Fda's CRL for Tabelecleucel
    Pierre Fabre Pharma Responds to Fda's CRL for Tabelecleucel

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-statement-regarding-receipt-of-complete-response-letter-for-tabelecleucel-biologics-license-application-from-the-us-food-and-drug-administration-302658114.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Pierre Fabre Announces Phase 3 Tabelecleucel Data in EBV+ PTLD
    Pierre Fabre Announces Phase 3 Tabelecleucel Data in EBV+ PTLD

    08 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-announces-updated-phase-3-tabelecleucel-data-at-american-society-of-hematology-meeting-in-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld-302634289.html

    PR NEWSWIRE
    08 Dec 2025
    Share Share
    Atara Bio Reports Q3 Financials & Operational Advancements
    Atara Bio Reports Q3 Financials & Operational Advancements

    12 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251112949094/en/Atara-Biotherapeutics-Announces-Third-Quarter-Financial-Results-and-Operational-Progress

    BUSINESSWIRE
    12 Nov 2025
    Share Share
    Pierre Fabre Pharma Acquires Tabelecleucel BLA For EBV+ PTLD
    Pierre Fabre Pharma Acquires Tabelecleucel BLA For EBV+ PTLD

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pierre-fabre-pharmaceuticals-announces-transfer-from-atara-biotherapeutics-of-the-biologics-license-application-bla-for-tabelecleucel-as-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv--302601901.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Atara Biotherapeutics Updates on Ebvallo Regulatory Status
    Atara Biotherapeutics Updates on Ebvallo Regulatory Status

    05 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250505744665/en/Atara-Biotherapeutics-Provides-Regulatory-Updates-on-EBVALLO-tabelecleucel

    BUSINESSWIRE
    05 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.